Diagnostic value and significance of serum miR-132 combined with miR-223 for sepsis-induced cardiomyopathy

YANPING LI, BIN LU, MUMING YU, JIANHUA ZHAI, YING YAO and YANFEN CHAI

Department of Emergency Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China

Received July 6, 2020; Accepted February 1, 2021

DOI: 10.3892/etm.2021.10832

Abstract. In previous studies, miR-132 and miR-223 were considered to be involved in cellular and pathological processes of diseases. However, the role of early diagnosis and prognosis evaluation in sepsis-induced cardiomyopathy (SIC) remains unknown. The present study aimed to explore the diagnostic value of combined detection of miR-132 and miR-223 for SIC and their correlation with creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), tumor necrosis factor α (TNF-α), and interleukin-6 (IL-6). SIC patients (n=80) admitted to Tianjin Medical University General Hospital were assigned to the research group (RG), while 60 healthy participants receiving physical examinations at the same period were assigned to the control group (CG). Serum expression profiles of miR-132 and miR-223 were detected by the RT-qPCR. CK-MB and cTnI were assessed using chemiluminescence assay, and TNF-α and IL-6 by enzyme-linked immunosorbent assay (ELISA). Serum miR-132 and miR-223 levels were significantly lower in the RG than in the CG (P<0.001). The sensitivity and specificity for the diagnosis of SIC were 82.50 and 71.67% for miR-132, 95.00 and 61.67% for miR-223, as well as 86.25 and 86.67% for miR-132 combined with miR-223. Serum miR-132 and miR-223 levels were significantly higher in the survivor group than in the deceased group (P<0.001). The sensitivity and specificity for the prognosis of SIC were 85.96 and 65.22% for miR-132 combined with miR-223. Serum miR-132 and miR-223 were negatively correlated with serum CK-MB, cTnI, TNF-α, and IL-6 (P<0.001). miR-132 combined with miR-223 can be used for early diagnosis and prognostic evaluation of SIC, and the two are correlated with CK-MB, cTnI, TNF-α, and IL-6.

Introduction

Sepsis is an uncontrolled severe inflammatory response, and a common complication in patients in the ICU (1). According to statistics, the number of severe sepsis-related deaths each year is approximately 3.7 million, and the current mortality rate of sepsis in numerous countries remains high (2). Despite significant advancements in the diagnosis and treatment of sepsis over the past 30 years, sepsis remains the leading cause of death among patients, with a 30-day mortality rate of 47% (3,4). Acute organ dysfunction complicated by sepsis is termed sepsis-induced cardiomyopathy (SIC), and sepsis is aggravated once cardiac functions are impaired (5). Approximately 40% of patients with sepsis suffer from myocardial dysfunction, among which myocardial depression is a serious clinical symptom with a mortality of 70 to 90%, while the mortality for sepsis patients without cardiac dysfunction is 20% (6,7). Devoid of specific clinical symptoms in the early stage, early SIC is hard to be diagnosed (8). Thus, the identification of biomarkers involved in the occurrence and development of SIC is of great significance for the early diagnosis and prognosis evaluation of SIC.

micro-RNAs (miRNAs or miRs), non-coding RNAs with 21 to 23 nucleotides, not only regulate gene expression, but are also involved in numerous biological processes such as embryonic development, organogenesis, and human inflammatory diseases (9). Most of the studies on sepsis have centered on the screening of serum miRNA profiles in sepsis patients, and have identified several miRNAs (including miR-155, miR-223 and miR-146a) as potential diagnostic markers for severe sepsis (10,11). miR-132 is an endogenous small RNA that controls the post transcriptional regulation of gene expression through controlled degradation or transcriptional inhibition of mRNA, which can affect the pathogenesis of numerous diseases (12). miR-223 is widely involved in the regulation of cellular processes and numerous types of pathological processes, such as cancer, autoimmune and inflammatory diseases (13). In a study by Li et al (14), hesperidin could alleviate lipopolysaccharide-induced neuroinflammation in mice by promoting miR-132 expression. In a previous study (15), serum miR-146a and miR-223 were markedly reduced in patients with sepsis, indicating the two can function as new markers for the diagnosis of sepsis. However, the roles of miR-132 and miR-223 in SIC are not clear. The myocardial toxicity induced by sepsis is mainly related to the reduction
of cardiac energy, impaired myocardial contractility, and the process of inflammatory cytokines. The treatment of sepsis mainly includes optimizing myocardial function and improving inflammatory response (16). Therefore, markers of myocardial injury and inflammatory response are essential for detecting the occurrence and development of SIC.

The present research determined the serum expression profiles of miR-132 and miR-223 in SIC patients, analyzed the value of combined serum miR-132 and miR-223 in the early diagnosis and prognosis prediction of SIC, and investigated the correlation of miR-132 and miR-223 with myocardial injury and inflammatory response markers.

**Materials and methods**

**General data.** A total of 80 SIC patients admitted to Tianjin Medical University General Hospital (Tianjin, China) were enrolled in the research group (RG), including 45 males and 35 females, aged from 24 to 81 years, with an average age of 58.6±11.3 years. Sixty healthy participants receiving physical examinations were enrolled in the control group (CG), including 31 males and 29 females, aged from 19 to 79 years, with an average age of 56.2±9.6 years. The guardians of the participants or the patients themselves had full knowledge of this research and signed the informed consent form and had complete clinical data. With no violation of ethics and morality, this research was carried out after obtaining approval from the Ethics Committee of Tianjin Medical University General Hospital.

**Inclusion and exclusion criteria.** The inclusion criteria was as follows: Patients diagnosed with sepsis according to the diagnostic criteria issued by the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) (17); patients aged from 19 to 81 years; patients with complete clinical data; patients with a white blood cell (WBC) count of over 12×10⁹/l, a heart index of over 3.5 l/(min· m²), a systolic blood pressure of <90 mmHg, a mixed venous oxygen saturation of over 70%, and a mean arterial pressure of <70 mmHg according to the laboratory tests. The exclusion criteria were as follows: Patients with a history of cardiac surgery; patients with autoimmune diseases, congenital heart disease, acute pulmonary embolism, cerebrovascular disease, myocarditis, coronary heart disease, acute pulmonary heart disease, mental illness, acute coronary syndrome, malignant tumors, congestive heart failure, liver and kidney dysfunction; patients with an exposure to other myocardial toxic substances such as doxorubicin, drugs, and alcohol. The aforementioned inclusion and exclusion criteria were applied to the RG. Participants included in the CG were healthy individuals.

**Detection methods.** Elbow venous blood (5 ml) was obtained from participants within 24 h after admission and placed in a vacuum blood collection tube. After centrifugation at 1,500 x g and 4°C for 15 min, the serum was stored in an EP at -80˚C. Serum expression profiles of creatine kinase isoenzyme (CK-MB) (cat. no. D711191), cardiac troponin I (cTnI) (cat. no. D711127), tumor necrosis factor-α (TNF-α) (cat. no. D721026) and interleukin-6 (IL-6) (cat. no. D711013) were determined by enzyme-linked immunosorbent assay (ELISA) (18). Human TNF-α, IL-6, and ELISA kits were manufactured by Sangon Biotech (Shanghai) Co., Ltd., China and were used according to the manufacturer's instructions. The optical density (OD) of each well was measured with a SpectraMax M multi-mode microplate reader (Shanghai Molecular Devices Co., Ltd.), and the TNF-α and IL-6 levels were determined.

**Reverse transcription-quantitative (RT-q)PCR detection.** Total RNA extraction was performed using an TRIzol kit (cat. no. 10296010; Invitrogen; Thermo Fisher Scientific, Inc.) in line with the instructions of the manufacturer. The concentration and purity of RNA were determined by DR6000 UV-Vis spectrophotometer (Shanghai Hach Water Analysis Instrument Co., Ltd.). RNA was reversely transcribed into cDNA according to the instructions of the PrimeScript RT kit (cat. no. RR047Q; Takara Bio, Inc.) and then stored at -20°C. U6 was used as the internal reference gene. Primer sequences are presented in Table I. The primers were designed and synthesized by Thermo Fisher Scientific, Inc. The RT-qPCR reaction was performed on an ABI PRISM 7500 fluorescence quantitative PCR instrument using SYBR Green Master Mix (cat. no. A46113; Thermo Fisher Scientific, Inc.). Conditions for the amplification were as follows: 95°C for 15 sec, proceeding with 40 cycles at 60°C for 30 sec, and 72°C for 30 sec. Amplification data analysis was performed according to SDS 2.0.1 (Thermo Fisher Scientific Co., Ltd., Shanghai, China). The results were expressed using 2^−ΔΔCt (19).

**Statistical analysis.** Statistical analysis was performed using SPSS 22.0 (IBM Corp.) and data visualization using GraphPad Prism 8 (GraphPad Software, Inc.). The counting data were represented by [n (%)] and their intergroup comparison was analyzed by the Chi-square test. The measurement data were represented by the mean ± standard deviation and their intergroup comparison was analyzed by the independent t-test. The value of miR-132 and miR-223 single or combined detection in SIC diagnosis was analyzed by the logistic regression equation and the receiver operating characteristic (ROC) curve. The correlation of serum miR-132 and miR-223 with CK-MB, cTnI, TNF-α, ad IL-6 was determined by the Pearson correlation coefficient. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**General data of the RG and CG groups.** No marked significance was observed between the RG and the CG with regard to sex ratio, body mass index (BMI), age, smoking, drinking, place of residence, educational level, alanine aminotransferase (ALT), aspartate aminotransferase (AST), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (P>0.05; Table II).

**Expression of serum miR-132 and miR-223 in RG and CG and their diagnostic value for SIC.** The relative levels of serum miR-132 and miR-223 in the CG and the RG were (1.43±0.57), (0.82±0.33) and (2.02±0.83), (1.09±0.42) respectively. The relative expression of miR-132 and miR-223 in the RG was...
significantly lower than that in the CG (P<0.001). According to the ROC curves demonstrating the diagnosis of SIC by serum miR-132 and miR-223, the AUC of SIC diagnosis of miR-132 and miR-223 was 0.827 and 0.831, respectively; the sensitivity of miR-132 and miR-223 was 82.50 and 95.00%, respectively; the specificity of miR-132 and miR-223 was 71.67 and 61.67%, respectively; the optimal cut-off value was 1.08 for miR-132 and 1.74 for miR-223. Using miR-132 and miR-223 as independent variables, the binomial logistic regression analysis was performed to obtain a logistic regression model: Logit (P)=7.555+3.133 miR-132+2.655 miR-223. In the diagnosis of SIC by this model, the AUC was 0.922, the sensitivity was 86.25%, the specificity was 86.67%, and the cut-off value was 0.63 (Table III; Fig. 1).
Serum expression profiles of miR-132 and miR-223 in the survivor group (SG) and deceased group (DC) and their prognostic value for SIC. According to the 30-day survival of SIC patients, RG was divided into the SG (n=57) and the DG (n=23). Serum miR-132 and miR-223 levels were (0.89±0.33) and (1.19±0.43) in the SG and (0.64±0.33) and (0.86±0.29) in the DG, respectively. Serum miR-132 and miR-223 levels were significantly higher in the SG than in the DG (P<0.001). According to the ROC curves demonstrating the prognosis prediction of SIC by serum miR-132 and miR-223, the AUC of prognosis prediction of miR-132 and miR-223 was 0.703 and 0.753, respectively; the sensitivity of miR-132 and miR-223 was 82.46 and 56.14%, respectively; the specificity of miR-132 and miR-223 was 60.87 and 82.61%, respectively; the optimal cut-off value was 0.64 for miR-132 and 1.06 for miR-223. Using miR-132 and miR-223 as independent variables, the binomial logistic regression analysis was performed to obtain a logistic regression model: Logit (P)=−2.725++2.124 miR-132++1.970 miR-223. In the diagnosis prediction of SIC by this model, the AUC was 0.773, the sensitivity was 85.96%, the specificity was 65.22%, and the cut-off value was 0.62 (Table IV; Fig. 2).

Correlation of serum miR-132 and miR-223 with markers for myocardial injury and inflammatory response. The serum levels of CK-MB, cTnI, TNF-α, and IL-6 were significantly higher in the RG than in the CG (P<0.001). Pearson correlation analysis revealed negative correlations of serum miR-132 and miR-223 levels with serum levels of CK-MB, cTnI, TNF-α, and IL-6 (r=-0.633, P<0.001; r=-0.532, P<0.001; r=-0.483, P<0.001; r=-0.496, P<0.001; r=-0.603, P<0.001; r=-0.616, P<0.001; r=-0.568, P<0.001; r=-0.511, P<0.001) (Figs. 3 and 4).

Discussion

SIC is a common myocardial complication in patients with sepsis, and its severity poses a threat to human health (20). Research has revealed that numerous miRNAs, including miR-146a, miR-223 and miR-21-3p, are valuable in the
critical regulation of sepsis combined with cardiac dysfunction, although their mechanisms have yet to be elucidated (21). Studies on miR-132 and miR-223 in sepsis are numerous. In a study by Liu et al (22), miR-132 inhibited
inflammation responses in lung injury models induced by sepsis. Moreover, the transfection of miR-132 mimics into macrophages pre-processed with acetylcholine inhibited the pro-inflammatory response following lipopolysaccharide challenge by inhibiting NF-κB and STAT3 pathways, and the transfection of miR-132 inhibitors into macrophages pre-processed with acetylcholine promoted the production of TNF-α, IL-1β, and IL-6. A study by Essandoh and Fan (23) reported that miR-223 levels were markedly lower in surviving sepsis patients than in non-surviving sepsis patients, suggesting that a lower miR-223 expression level may result in septic death. miR-132 and miR-223 are potentially important in SIC. Previous studies have focused mostly on the mechanism of action of miR-132 and miR-223 in sepsis (24,25). The diagnostic value of the combination of miR-132 and miR-223 in SIC is unclear. In the present study, the serum levels of miR-132 and miR-223 were significantly downregulated in SIC patients. The combination of the two revealed a good diagnostic value. A previous study (26) discovered that the loss of miR-223 double-stranded (5p and 3p) aggravated the inflammatory response and myocardial dysfunction of multiple sepsis, causing higher mortality. In the present study it was hypothesized that miR-132 and miR-223 may affect the prognosis of SIC. The results revealed that miR-132 combined with miR-223 had a predictive value in the survival of SIC patients. Thus, they are both significant in the early diagnosis and prognosis prediction of SIC.

Inflammatory cytokines including TNF-α and IL-6 that are excessively released in sepsis patients are associated with cardiac dysfunction (27). CK-MB and cTnI are markers and indicators of myocardial damage, and they can rapidly increase after myocardial damage (28). In a study by Qin et al (29), the myocardial enzyme indexes (including CK-MB and cTnI) and inflammation indexes (including TNF-α and IL-6) of a rat model of myocardial injury induced by sepsis were markedly increased, and the use of erythropoietin protected the heart from sepsis-induced myocardial injury. Markers of myocardial injury and inflammatory response play an important role in SIC. In the present study, the levels of serum CK-MB, cTnI, TNF-α and IL-6 were markedly increased in SIC patients, and miR-132 and miR-223 were both negatively correlated with CK-MB, cTnI, TNF-α, and IL-6. In a previous study (30), the decrease in miR-132 expression increased the levels of TNF-α, IL-1β, and IL-6 and promoted cell apoptosis. In addition, the overexpression of miR-132 played a protective role in rat models with cerebral hemorrhage. A previous study (31) revealed that the high miR-223 level in WT-exosomes was transmitted to cardiomyocytes and in turn led to a decrease in TNF-α, IL-1β, and IL-6, protecting septic patients from myocardial damage induced by mesenchymal stem cells. Hence, the downregulation of miR-132 and miR-223 in SIC may be related to myocardial injury and upregulation of inflammatory factors, but the specific mechanism remains to be elucidated.

The present study confirmed the favorable role of miR-132 and miR-223 combined detection in the early diagnosis and prognosis evaluation of SIC. miR-132 and miR-223 exhibited an inhibitory gene effect in SIC, however, *in vivo* experiments...
were not conducted. These two miRNAs and their target targets may function in SIC, however the specific regulatory mechanism remains to be elucidated. Furthermore, the present research included individuals undergoing health checkups instead of sepsis in the CG. These shortcomings warrant improvement in future studies to better support the results.

Figure 4. Correlation of serum miR-132 and miR-223 levels with serum levels of CK-MB, cTnI, TNF-α, and IL-6 in the research group. (A-D) Serum miR-132 level was negatively correlated with CK-MB, cTnI, TNF-α, and IL-6 levels (r = -0.633, P < 0.001; r = -0.532, P < 0.001; r = -0.483, P < 0.001; r = -0.496, P < 0.001). (E-H) Serum miR-223 level was negatively correlated with CK-MB, cTnI, TNF-α, and IL-6 levels (r = -0.603, P < 0.001; r = -0.616, P < 0.001; r = -0.568, P < 0.001; r = -0.511, P < 0.001). miR, microRNA; CK-MB, creatine kinase-MB; cTnI, cardiac troponin I; TNF-α, tumor necrosis factor α; IL, interleukin.
In summary, the combined detection of miR-132 and miR-223 can be used for early diagnosis and prognostic evaluation of SIC, and these two miRNAs were revealed to be correlated with CK-MB, cTnI, TNF-α, and IL-6 levels.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YL and YC designed the study and drafted the manuscript. YL, BL, MY, JZ and YY were responsible for the collection and analysis of the experimental data. JZ, YY and YC revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Tianjin Medical University General Hospital (Tianjin, China). Patients who participated in this research, signed the informed consent and had complete clinical data.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sato R, Kuriyama A, Takada T, Nasu M and Luthe SK: Prevalence and risk factors of sepsis-induced cardiomyopathy: A retrospective cohort study. Medicine (Baltimore) 95: e5031, 2016.
2. Yang F, Zhao LN, Sun Y and Chen Z: Levisomendan as a new force in the treatment of sepsis-induced cardiomyopathy: Mechanism and clinical application. J Int Med Res 47: 1817-1828, 2019.
3. Dombrowski SS, Martin AA, Sunderland J and Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 35: 1244-1250, 2007.
4. Russell JA and Walley KR: Update in sepsis 2012. Am J Respir Crit Care Med 187: 1303-1307, 2013.
5. Smerarso N, Ammollo CT, Smerarso F and Colucci M: Sepsis, thrombosis and organ dysfunction. Thromb Res 129: 290-295, 2012.
6. Hochstadt A, Merzoy Y and Landesberg G: Myocardial dysfunction in severe sepsis and septic shock: More questions than answers? J Cardiothorac Vasc Anesth 25: 526-535, 2011.
7. Romero-Bermejo FJ, Ruiz-Bailen M, Gil-Cebrian J and Huertos-Rancho MJ: Sepsis-induced cardiomyopathy. Curr Cardiol Rev 7: 163-183, 2011.
8. Sato R and Nasu M: A review of sepsis-induced cardiomyopathy. J Intensive Care 3: 48, 2015.
9. An R, Feng J, Xi C, Xu J and Sun L: miR-146a attenuates sepsis-induced myocardial dysfunction by suppressing IRAK1 and TRAP6 via targeting ErbB4 expression. Oxid Med Cell Longev 2018: 7163057, 2018.
10. Sluiter JP and Doevendans PA: Sepsis-associated cardiac dysfunction is controlled by small RNA molecules. J Mol Cell Cardiol 97: 67-69, 2016.
11. Zheng G, Pan M, Jin W, Jin G and Huang Y: MicroRNA-135a is up-regulated and aggravates myocardial depression in sepsis via regulating p38 MAPK/NF-κB pathway. Int Immunopharmacol 45: 6-12, 2017.
12. Qian Y, Song J, Ouyang Y, Han Q, Chen W, Zhao X, Xie Y, Chen Y, Yuan W and Fan C: Adhimal role of miR-132 in the nervous system. Front Pharmacol 8: 770, 2017.
13. Mancuso R, Agostini S, Hernis A, Zanzottera M, Bianchi A and Clerici M: Circulatory miR-223-3p discriminates between Parkinson's and Alzheimer's patients. Sci Rep 9: 9393, 2019.
14. Li M, Shao H, Zhang X and Qin D: Herpesvirus alleviates lipopolysaccharide-induced neuroinflammation in mice by promoting the miRNA-132 pathway. Inflammation 39: 1681-1689, 2016.
15. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, Wan XJ and Zhu KM: Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 394: 184-188, 2010.
16. Wang H, Bei Y, Shen S, Huang P, Shi J, Zhang J, Sun Q, Chen Y, Yang Y, Xu T et al.: miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2. J Mol Cell Cardiol 94: 213-223, 2016.
17. Hashmat N, Shabbir I, Rahat T, Ijaz F and Majeed S: Clinical profile and disease outcome of septic patients at public sector hospital. Pak J Med Res 54: 44-47, 2015.
18. Zhuang YT, Xu DY, Wang GY, Sun JL, Huang J and Wang SZ: IL-6 induced LncRNA MALAT1 enhances NF-κB expression in LPS-induced septic cardiomyocytes via activation of SAA3. Eur Rev Med Pharmacol Sci 21: 302-309, 2017.
19. Zhao A, Li G, Péoch M, Genin C and Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94: 115-120, 2013.
20. Kakihana Y, Ito T, Nakahara M, Yamaguchi K and Yasuda T: Sepsis-induced myocardial dysfunction: Pathophysiology and management. J Intensive Care 4: 22, 2016.
21. Wang H, Bei Y, Huang P, Zhou Q, Shi J, Sun Q, Zhong J, Li X, Kong X and Xiao J: Inhibition of miR-155 protects against LPS-induced cardiac dysfunction and apoptosis in mice. Mol Ther Nucleic Acids 5: e374, 2016.
22. Liu F, Li Y, Jiang R, Nie C, Zeng Z, Zhao N, Huang C, Shao Q, Ding C, Qing C, et al.: miR-132 inhibits lipopolysaccharide-induced inflammation in alveolar macrophages by the cholinergic anti-inflammatory pathway. Exp Lung Res 41: 261-269, 2015.
23. Essandoh K and Fan GC: Role of extracellular and intracellular microRNAs in sepsis. Biochim Biophys Acta 1824: 2155-2160, 2015.
24. Nahid MA, Yao B, Dominguez-Gutierrez PR, Kesavalu L, Satoh M and Chan KE: Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. J Immunol 190: 1250-1263, 2013.
25. Xie F: The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Med Immunol 303: 1-6, 2016.
26. Wang X, Huang W, Yang Y, Wang Y, Peng T, Chang J, Caldwell CC, Zingarelli B and Fan GC: Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. Biochim Biophys Acta 1842: 701-711, 2014.
27. Chen H, Wang X, Yan X, Cheng X, He X and Zheng W: LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFκB. Int Immunopharmacol 55: 69-76, 2018.
28. Liu J, Li J, Tian P, Guli B, Weng G, Li L and Cheng Q: H3S attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Exp Ther Med 17: 4064-4072, 2018.
29. Qian Y, Song J, Ouyang Y, Han Q, Chen W, Zhao X, Xie Y, Chen Y, Yuan W and Fan C: Adhimal role of miR-132 in the nervous system. Front Pharmacol 8: 770, 2017.
30. Qian Y, Song J, Ouyang Y, Han Q, Chen W, Zhao X, Xie Y, Chen Y, Yuan W and Fan C: Adhimal role of miR-132 in the nervous system. Front Pharmacol 8: 770, 2017.